Oramed Files 10-K/A, Confirms Compliance for FY24
Ticker: ORMP · Form: 10-K/A · Filed: Jul 16, 2025 · CIK: 1176309
| Field | Detail |
|---|---|
| Company | Oramed Pharmaceuticals Inc. (ORMP) |
| Form Type | 10-K/A |
| Filed Date | Jul 16, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: 10-K/A, SEC Filing, Regulatory Compliance, Pharmaceuticals, Smaller Reporting Company, Annual Report Amendment, Corporate Governance
Related Tickers: ORMP
TL;DR
**ORMP's 10-K/A is a routine compliance update, signaling no major operational shifts but reinforcing regulatory adherence.**
AI Summary
ORAMED PHARMACEUTICALS INC. filed a 10-K/A on July 16, 2025, for the fiscal year ended December 31, 2024, amending its annual report. The company, a non-accelerated filer and smaller reporting company, confirmed it has filed all required reports under Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months and has been subject to such filing requirements for the past 90 days. Oramed also confirmed electronic submission of all Interactive Data Files required by Rule 405 of Regulation S-T during the preceding 12 months. The amendment itself does not provide specific revenue or net income figures, nor does it detail key business changes or strategic outlook, focusing instead on regulatory compliance and company classification. The filing indicates Oramed is not a well-known seasoned issuer. Its common stock, with a par value of $0.012, is traded on the Nasdaq Capital Market and the Tel Aviv Stock Exchange under the symbol ORMP. The company's business address is 1185 Avenue of the Americas, Third Floor, New York, NY 10036.
Why It Matters
This 10-K/A filing primarily serves to correct or update information in Oramed's original 10-K, ensuring regulatory compliance for investors. For investors, it signals that the company is diligently meeting its reporting obligations, which can build confidence in its governance. Employees and customers are less directly impacted by this specific amendment, as it doesn't detail operational changes or product developments. In a competitive pharmaceutical landscape, consistent and accurate SEC filings are crucial for maintaining transparency and investor trust, especially for a smaller reporting company like Oramed competing with larger, more established players.
Risk Assessment
Risk Level: low — The risk level is low because this 10-K/A filing is an amendment to a previously filed annual report, primarily confirming regulatory compliance and company classification (non-accelerated filer, smaller reporting company). It does not introduce new significant risks or financial disclosures that would materially alter the company's risk profile. The filing explicitly states Oramed has filed all required reports and submitted all Interactive Data Files, indicating good standing with SEC regulations.
Analyst Insight
Investors should view this 10-K/A as a standard regulatory update, not a catalyst for immediate action. It confirms Oramed's compliance with SEC reporting requirements for the fiscal year ended December 31, 2024. Focus on the underlying financial performance and pipeline developments detailed in the original 10-K, as this amendment provides no new financial or operational data.
Key Numbers
- $0.012 — Common Stock Par Value (The par value of Oramed's common stock, traded on Nasdaq and Tel Aviv Stock Exchange.)
Key Players & Entities
- ORAMED PHARMACEUTICALS INC. (company) — Registrant and filer of 10-K/A
- SEC (regulator) — Securities and Exchange Commission
- Nasdaq Capital Market (company) — Exchange where ORMP common stock is registered
- Tel Aviv Stock Exchange (company) — Exchange where ORMP common stock is registered
- $0.012 (dollar_amount) — Par value of common stock
- December 31, 2024 (date) — Fiscal year end for the report
- July 16, 2025 (date) — Filing date of the 10-K/A
- 001-35813 (regulator) — Commission file number
- 1185 Avenue of the Americas, Third Floor, New York, NY 10036 (company) — Principal Executive Offices address
- 98-0376008 (company) — I.R.S. Employer Identification No.
FAQ
What is the purpose of ORAMED PHARMACEUTICALS INC.'s 10-K/A filing?
The 10-K/A filing by ORAMED PHARMACEUTICALS INC. is an amendment to its annual report for the fiscal year ended December 31, 2024, primarily to confirm regulatory compliance and company classification, such as being a non-accelerated filer and smaller reporting company.
When was ORAMED PHARMACEUTICALS INC.'s 10-K/A filed?
ORAMED PHARMACEUTICALS INC.'s 10-K/A was filed on July 16, 2025, for the fiscal year ended December 31, 2024.
Is ORAMED PHARMACEUTICALS INC. a well-known seasoned issuer?
No, ORAMED PHARMACEUTICALS INC. indicated in its 10-K/A filing that it is not a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.
On which exchanges is ORAMED PHARMACEUTICALS INC.'s common stock traded?
ORAMED PHARMACEUTICALS INC.'s common stock, with a par value of $0.012, is traded on both the Nasdaq Capital Market and the Tel Aviv Stock Exchange under the symbol ORMP.
Has ORAMED PHARMACEUTICALS INC. filed all required reports in the last 12 months?
Yes, ORAMED PHARMACEUTICALS INC. confirmed in its 10-K/A that it has filed all reports required by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months.
What is ORAMED PHARMACEUTICALS INC.'s business address?
ORAMED PHARMACEUTICALS INC.'s principal executive offices are located at 1185 Avenue of the Americas, Third Floor, New York, NY 10036.
What is ORAMED PHARMACEUTICALS INC.'s fiscal year end?
ORAMED PHARMACEUTICALS INC.'s fiscal year ends on December 31, as indicated in the 10-K/A filing for the period ended December 31, 2024.
Is ORAMED PHARMACEUTICALS INC. considered a smaller reporting company?
Yes, ORAMED PHARMACEUTICALS INC. indicated in its 10-K/A filing that it is a smaller reporting company.
Did ORAMED PHARMACEUTICALS INC. submit all required Interactive Data Files?
Yes, ORAMED PHARMACEUTICALS INC. confirmed in its 10-K/A that it has submitted electronically every Interactive Data File required pursuant to Rule 405 of Regulation S-T during the preceding 12 months.
What is the significance of the 10-K/A for ORAMED PHARMACEUTICALS INC. investors?
For ORAMED PHARMACEUTICALS INC. investors, the 10-K/A signifies the company's ongoing commitment to regulatory transparency and compliance, confirming that it meets its reporting obligations for the fiscal year ended December 31, 2024, without introducing new material financial or operational changes.
Industry Context
Oramed Pharmaceuticals operates within the highly competitive pharmaceutical and biotechnology sector, focusing on drug development. This industry is characterized by significant research and development costs, lengthy regulatory approval processes, and intense competition from both established pharmaceutical giants and emerging biotech firms. Trends include a growing emphasis on specialized therapies, advancements in drug delivery systems, and increasing regulatory scrutiny.
Regulatory Implications
As a pharmaceutical company, Oramed is subject to stringent regulations from bodies like the FDA. The filing of an amended 10-K, even if for procedural reasons, underscores the importance of accurate and timely disclosure. Any missteps in regulatory compliance or clinical trial reporting could lead to significant delays, financial penalties, or reputational damage.
What Investors Should Do
- Review original 10-K filing
- Monitor future SEC filings
- Assess Nasdaq and TASE trading activity
Key Dates
- 2025-07-16: 10-K/A Filing — Amendment filed for the fiscal year ended December 31, 2024, indicating updates or corrections to the original annual report.
Glossary
- 10-K/A
- An amended annual report filed with the SEC, used to correct or supplement information previously filed in a Form 10-K. (This filing is an amendment to Oramed's annual report, suggesting a need for revisions to the original filing.)
- Non-accelerated filer
- A company that does not meet the criteria for accelerated or large accelerated filer status, typically based on public float and filing history. (Oramed's classification as a non-accelerated filer indicates it is subject to less stringent reporting deadlines and requirements compared to larger companies.)
- Smaller reporting company
- A company that meets certain thresholds for public float and annual revenue, allowing for scaled disclosure requirements. (This classification, along with non-accelerated filer status, suggests Oramed is a smaller entity with potentially fewer resources for extensive reporting.)
- Rule 405 of Regulation S-T
- Requires companies to submit all Interactive Data Files electronically, including financial statements and related information formatted in XBRL. (Oramed's confirmation of electronic submission under this rule highlights its compliance with modern digital reporting standards.)
- Well-known seasoned issuer
- A company that meets specific criteria related to its public float, reporting history, and debt issuance, allowing for streamlined registration of securities. (Oramed's status as not a well-known seasoned issuer means it does not benefit from the simplified registration processes available to such companies.)
- Par value
- A nominal value assigned to a share of stock by the company's charter, often a very small amount. (The $0.012 par value for Oramed's common stock is a legally defined minimum value, distinct from its market trading price.)
Year-Over-Year Comparison
This filing is an amendment (10-K/A) to the annual report for the fiscal year ended December 31, 2024. As such, it primarily serves to correct or supplement information from the original 10-K. Without access to the original 10-K and the specific details of the amendment, a direct comparison of key metrics like revenue growth, margin changes, or new risks is not possible from this document alone. The filing confirms Oramed's status as a non-accelerated filer and smaller reporting company, which is consistent with its operational scale.
Filing Details
This Form 10-K/A (Form 10-K/A) was filed with the SEC on July 16, 2025 regarding ORAMED PHARMACEUTICALS INC. (ORMP).